- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects (clinicaltrials.gov) - Sep 5, 2017
P1, N=50, Completed,
Active, not recruiting --> Completed
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 21, 2017
P2, N=50, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects (clinicaltrials.gov) - Jun 20, 2017
P1, N=50, Active, not recruiting,
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 6, 2015
P3, N=596, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Apr 2014
- |||||||||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Trial completion: A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 5, 2015
P3, N=584, Completed,
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Apr 2014 Active, not recruiting --> Completed
- |||||||||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Trial primary completion date: A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jun 11, 2015
P3, N=584, Active, not recruiting,
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Nov 2014
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Apr 15, 2015
P3, N=498, Active, not recruiting,
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Jun 2014 --> Nov 2014
- |||||||||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Enrollment closed: A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Feb 26, 2014
P3, N=584, Active, not recruiting,
Trial primary completion date: Jun 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- |||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
Trial completion: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects (clinicaltrials.gov) - Feb 26, 2014
P1, N=159, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Dec 9, 2013
P3, N=498, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects (clinicaltrials.gov) - Dec 9, 2013
P1, N=138, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
New P1 trial: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects (clinicaltrials.gov) - Aug 12, 2013
P1, N=159, Completed,
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jul 8, 2013
P3, N=498, Active, not recruiting,
- |||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects (clinicaltrials.gov) - May 29, 2013
P1, N=138, Completed,
|
